Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Amneal Pharmaceuticals, Inc, CL-A stake
total: 670
Viking Global Investors AMRX trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2018 Q3
- Held for:
- 2 quarters
- Latest activity:
- 2019 Q1
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Amneal Pharmaceuticals, Inc, CL-A (AMRX) shares. To date, the estimated cost basis is nearly $19.19 for "buy" trades and estimated average "sell" price is $13.53. Viking Global Investors first purchased AMRX in 2018 Q3, initially acquiring about 1.54M shares. Since the initial investment in Amneal Pharmaceuticals, Inc, CL-A (AMRX), Viking Global Investors has made 2 more transactions.
When did Ole Andreas Halvorsen sell Amneal Pharmaceuticals, Inc, CL-A (AMRX)?
Ole Andreas Halvorsen sold off the entire Amneal Pharmaceuticals, Inc, CL-A (AMRX) position in 2019 Q1.
When did Ole Andreas Halvorsen buy Amneal Pharmaceuticals, Inc, CL-A (AMRX)?
Ole Andreas Halvorsen first invested in Amneal Pharmaceuticals, Inc, CL-A (AMRX) in 2018 Q3 at the reported quarter-end price of $22.19 per share.
What's the cost basis of Viking Global Investors's AMRX stake?
The estimated cost basis for Amneal Pharmaceuticals, Inc, CL-A (AMRX) stake is around $19.19 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $19.19
- Weighted AVG sell price:
- $13.53
Ole Andreas Halvorsen's historical trades in Amneal Pharmaceuticals, Inc, CL-A
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.